Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor‑negative breast cancer cells

Zhao,Xiao‑Dan; Dong,Ni; Man,Hong‑Tao; Fu,Zhong‑Lin; Zhang,Mei‑Hong; Kou,Shuang; Ma,Shi‑Liang

doi:10.3892/br.2013.150

Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor‑negative breast cancer cells

Authors:
- Xiao‑Dan Zhao
- Ni Dong
- Hong‑Tao Man
- Zhong‑Lin Fu
- Mei‑Hong Zhang
- Shuang Kou
- Shi‑Liang Ma
View Affiliations

Affiliations: College of Bioscience and Biotechnology, Shenyang Agricultural University, Shenyang, Liaoning 110866, P.R. China
Published online on: July 22, 2013 https://doi.org/10.3892/br.2013.150
Pages: 797-801

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ginkgo biloba is a dioecious tree and its extract is a complex mixture that has been used for thousands of years to treat a variety of ailments in traditional Chinese medicine. The aim of this study was to present our observations on the inhibitory effects of different Ginkgo biloba extracts on human breast cancer cell proliferation and growth. Our results demonstrated that treatment of MCF‑7 and MDA‑MB‑231 human breast cancer cells with Ginkgo biloba leaves and ginkgo fruit extract inhibited cell proliferation. it was also observed that this inhibition was accompanied by the enhancement of cytochrome P450 (CYP) 1B1 expression in MDA‑MB‑231 cells. In addition, treatment with ginkgo fruit extract resulted in a higher CYP1B1 expression in MDA‑MB‑231 cells compared to treatment with the Ginkgo biloba leaves extract. Our results suggested that the inhibitory effects of the Ginkgo biloba extract on estrogen receptor‑negative breast cancer proliferation and the induction of CYP1B1 expression may be exerted through an alternative pathway, independent of the estrogen receptor or the aryl hydrocarbon receptor pathway.

View Figures

View References

1	McKenna DJ, Jones K and Hughes K: Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 7:70–86. 88–90. 2001.PubMed/NCBI
2	No authors listed. EGb 761: Ginkgo biloba extract, Ginkor. Drugs R D. 4:188–193. 2003. View Article : Google Scholar
3	Brunetti L, Orlando G, Menghini L, Ferrante C, Chiavaroli A and Vacca M: Ginkgo biloba leaf extract reverses amyloid beta-peptide-induced isoprostane production in rat brain in vitro. Planta Med. 72:1296–1299. 2006. View Article : Google Scholar
4	Maclennan KM, Darlington CL and Smith PF: The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 67:235–257. 2002.
5	Yao ZX, Han Z, Drieu K and Papadopoulos V: Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels. J Nutr Biochem. 15:749–756. 2004. View Article : Google Scholar
6	Gong QH, Wu Q, Huang XN, Sun AS, Nie J and Shi JS: Protective effect of Ginkgo biloba leaf extract on learning and memory deficit induced by aluminum in model rats. Chin J Integr Med. 12:37–41. 2006.
7	Hrehorovska M, Burda J, Domorakova I and Mechirova E: Effect of Tanakan on postischemic activity of protein synthesis machinery in the rat brain. Gen Physiol Biophys. 23:457–465. 2004.PubMed/NCBI
8	Koltermann A, Hartkorn A, Koch E, Furst R, Vollmar AM and Zahler S: Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 64:1715–1722. 2007. View Article : Google Scholar
9	Oh SM and Chung KH: Estrogenic activities of Ginkgo biloba extracts. Life Sci. 74:1325–1335. 2004. View Article : Google Scholar
10	Oh SM and Chung KH: Antiestrogenic activities of Ginkgo biloba extracts. J Steroid Biochem Mol Biol. 100:167–176. 2006. View Article : Google Scholar
11	Feng X, Zhang L and Zhu H: Comparative anticancer and antioxidant activities of different ingredients of Ginkgo biloba extract (EGb 761). Planta Med. 75:792–796. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chen XH, Miao YX, Wang XJ, et al: Effects of Ginkgo biloba extract EGb761 on human colon adenocarcinoma cells. Cell Physiol Biochem. 27:227–232. 2011.
13	Chao JC and Chu CC: Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol. 10:37–41. 2004.
14	Zhang Y, Chen AY, Li M, Chen C and Yao Q: Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J Surg Res. 148:17–23. 2008. View Article : Google Scholar
15	Xu AH, Chen HS, Sun BC, et al: Therapeutic mechanism of Ginkgo biloba exocarp polysaccharides on gastric cancer. World J Gastroenterol. 9:2424–2427. 2003.
16	Bernhardt R: Cytochromes P450 as versatile biocatalysts. J Biotechnol. 124:128–145. 2006. View Article : Google Scholar : PubMed/NCBI
17	Mao P, Qiao DJ and Ma XR: Cytochrome P450 and iatrology. Chin J Antibiot. 36:93–101. 2011.
18	Orellana M and Guajardo V: Cytochrome P450 activity and its alteration in different diseases. Rev Med Chil. 132:85–94. 2004.(In Spanish).
19	Oyama T, Kagawa N, Kunugita N, et al: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci. 9:1967–1976. 2004. View Article : Google Scholar : PubMed/NCBI
20	Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT and Burke MD: Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol. 169:347–353. 1993. View Article : Google Scholar : PubMed/NCBI
21	Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC and Pfeifer AM: Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer. 34:914–920. 1998. View Article : Google Scholar : PubMed/NCBI
22	Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC and Melvin WT: Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer. 79:1836–1842. 1999. View Article : Google Scholar : PubMed/NCBI
23	Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol. 192:419–426. 2000. View Article : Google Scholar : PubMed/NCBI
24	Hashizume T, Imaoka S, Mise M, et al: Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther. 300:298–304. 2002. View Article : Google Scholar : PubMed/NCBI
25	Bruno RD and Njar VC: Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 15:5047–5060. 2007. View Article : Google Scholar : PubMed/NCBI
26	Murray GI, Taylor MC, McFadyen MC, et al: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57:3026–3031. 1997.PubMed/NCBI
27	Gibson P, Gill JH, Khan PA, et al: Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther. 2:527–534. 2003.PubMed/NCBI
28	Tokizane T, Shiina H, Igawa M, et al: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 11:5793–5801. 2005. View Article : Google Scholar : PubMed/NCBI
29	Deng Y, Bi HC, Zhao LZ, et al: Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica. 38:465–481. 2008. View Article : Google Scholar : PubMed/NCBI
30	He N, Cai HB, Xie HG, Collins X, Edeki TI and Strom SC: Induction of cyp3a in primary cultures of human hepatocytes by ginkgolides A and B. Clin Exp Pharmacol Physiol. 34:632–635. 2007. View Article : Google Scholar : PubMed/NCBI
31	Li L, Stanton JD, Tolson AH, Luo Y and Wang H: Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 26:872–882. 2009.PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCTmethod. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Bhattacharyya KK, Brake PB, Eltom SE, Otto SA and Jefcoate CR: Identification of a rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue-specific pattern of hormonal and aryl hydrocarbon receptor-linked regulation. J Biol Chem. 270:11595–11602. 1995. View Article : Google Scholar
34	Shimada T, Oda Y, Gillam EM, Guengerich FP and Inoue K: Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM 2009. Drug Metab Dispos. 29:1176–1182. 2001.PubMed/NCBI
35	Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M and Yokoi T: Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 64:3119–3125. 2004. View Article : Google Scholar : PubMed/NCBI
36	Spink DC, Katz BH, Hussain MM, Pentecost BT, Cao Z and Spink BC: Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells. Carcinogenesis. 24:1941–1950. 2003. View Article : Google Scholar : PubMed/NCBI
37	Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N and Dahiya R: CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res. 63:3913–3918. 2003.PubMed/NCBI
38	Brockdorff BL, Skouv J, Reiter BE and Lykkesfeldt AE: Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines. Int J Cancer. 88:902–906. 2000. View Article : Google Scholar : PubMed/NCBI
39	Berge G, Mollerup S, Øvrebø S, et al: Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung. Lung Cancer. 45:289–297. 2004. View Article : Google Scholar : PubMed/NCBI
40	Buters JT, Sakai S, Richter T, et al: Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA. 96:1977–1982. 1999.
41	Dohr O, Vogel C and Abel J: Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells. Arch Biochem Biophys. 321:405–412. 1995. View Article : Google Scholar : PubMed/NCBI
42	Yoshioka H, Hiromori Y, Aoki A, et al: Possible aryl hydrocarbon receptor-independent pathway of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced antiproliferative response in human breast cancer cells. Toxicol Lett. 211:257–265. 2012. View Article : Google Scholar
43	Larsen MC, Angus WG, Brake PB, Eltom SE, Sukow KA and Jefcoate CR: Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res. 58:2366–2374. 1998.
44	Angus WG, Larsen MC and Jefcoate CR: Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status. Carcinogenesis. 20:947–955. 1999. View Article : Google Scholar : PubMed/NCBI